As the drumbeat for drug pricing reform has grown, two things are becoming clear: This issue is not going away, and Pharma’s time-worn rebuttals are increasingly unlikely to save the industry from political retribution. Now, the main question is whether drug companies have the foresight and will to voluntarily rein in prices before they’re subjected to a government-imposed solution.
